If you are interested in hearing the 2017 drug delivery landscape year in review in 2017, please email service@tcfllc.org Chair of the Partnership Opportunities in Drug Delivery (PODD) event, Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche, presents an annual year-in-review of the drug delivery landscape from 2016. Dr Lueckel’s opening remarks are a highlight of PODD every year, and we’re excited to have her return as program chair for the 2018 event, coming up on Octob...
Sep 26, 2017•25 min
Pan American Games Champion, Olympian and World Championship silver medalist, Jennifer Goldsack, became a world-class athlete while working and studying at the University of Oxford. How did she do it? She recently shared her story with DPharm Director, Valerie Bowling, discussing the lessons she learned from her Olympic experience and how she uses them in her professional life at the Clinical Trials Transformation Initiative (CTTI). Ms Goldsack manages the development and implementation of Clini...
Sep 22, 2017•20 min
Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including: Discovery / Preclinical ScienceTranslational ScienceClinical DevelopmentBusiness AspectsInvestor RelationsEmerging TechnologiesBiomarkers / DiagnosticsTrends in the Field Dr Axel Hoos, GSK and Dr James Gulley, NCI, together led the design of the 4th annual Immuno-Oncology 360° program to include 45 speakers and over 30 talks. Save the date:...
Sep 20, 2017•6 min
The Conference Forum is pleased to share a podcast featuring keynote speaker and world renowned customer service expert, Dr Chip Bell who spoke at the 6th annual DPharm: Disruptive Innovations to Advance Clinical Trials on the topic of service in clinical trials. To truly service our patients, we need to understand service together with science. Can service be a disrupter in clinical research? In this keynote, Dr Bell tells us how to think like a service industry, why it’s worth it for R&D a...
Aug 24, 2017•48 min
Originally recorded during the 4th annual Patients as Partners US event held in Philadelphia, March 2017, Bristol-Myers Squibb’s Mary Stober-Murray moderates this multi-stakeholder panel to discuss what patients truly want when it comes to clinical care and patient involvement. Patients John Creveling, a Parkinson’s Foundation Research Advocate, and Deb Maskens from the International Kidney Cancer Coalition, join her and representing the industry perspective are Paul Graves from Takeda Pharmaceu...
Jun 27, 2017•51 min
Internationally recognized digital health expert, Donald Jones, MBA, Chief Digital Officer at Scripps Translational Science Institute, shares his insights on the digital clinical trial landscape and the urgent need to pair digitization with drug products for patients during his keynote address from the 2016 CMO Summit. The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, i...
Jun 26, 2017•44 min
In this multi-stakeholder session from the 4th annual Patients as Partners US meeting, patients, advocates, industry and nonprofit organizations come together to discuss how they partnered and the outcomes of those partnerships. • What’s the roadmap? • What are the ways you have partnered with industry? • What are some best practices or rules of engagement? • How can the pharma industry better serve patient advocacy organizations? • How are we creating and ruthlessly maintaining transparency and...
Jun 23, 2017•41 min
Adapted from the 2016 Chief Medical Officer Summit keynote address, Dr Akshay Vaishnaw, who serves as EVP of R&D and CMO at Alnylam Pharmaceuticals, tackles the challenges and opportunities in pursuing a new therapeutic modality from its inception. The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, in Boston.
Jun 23, 2017•37 min
At the 2017 Partners Europe event in London, Nicholas Brooke, Chief Executive, Patient Focused Medicines Development (PFMD) and Jan Geissler, Director, European Patients’ Academy on Therapeutic Innovation (EUPATI) call on industry to partner with patients in the development and lifecycle of medicines. The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patien...
Jun 22, 2017•36 min
Dr Axel Hoos, GSK, leads a panel discussion on Trends and Collaborations in the Immuno-Oncology Space, featuring Dr Ramy Ibrahim, VP and Head of R&D, Parker Institute for Cancer Immunotherapy; Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs, Cancer Research Institute; Dr Daniel Chen, VP, Global Head of Cancer Immunotherapy Development, Genentech; and David Wholley, MPhil, Director, Research Partnerships Division, Foundation for the National Institutes of Health. The 4th Annu...
Jun 22, 2017•42 min
At the inaugural Patients as Partners Europe event, Duncan Arbour from inVentiv Health explores the ‘how’ and ‘when’ for involving patients within clinical and commercial to enhance the development and delivery of innovative therapies. The patient voice as a strategic driver is being included much earlier in the development process than ever before. In this session, pharmaceutical, biotech and device companies will gain insight into the value of smarter patient integration. Key focus areas inclu...
Jun 21, 2017•12 min
Alastair Kent, Director of the Genetic Alliance UK, talks about how patients can and are influencing policy within the EU. The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.
Jun 21, 2017•31 min
Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. Dr Hoos returns as lead advisor, as well as moderating a talk called, "Investor Roundtable: The Role of IO within Large Pharma - Where Does it Stand?" with panelists from Citi, Atlas Venture, New Enterprise Associates, and SR One Ltd.
Jun 21, 2017•25 min
Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. About Dr Cesano: Alessandra Cesano, MD, PhD has served as CMO at nanoString since July 2015. Prior to...
Jun 20, 2017•22 min
Originally recorded at the inaugural Patients as Partners Europe event, held in London in February 2017. Patient, industry, and regulatory perspectives are provided by Alastair Kent of Genetic Alliance UK, Dr Anton Hoos of Amgen Europe, and Isabelle Moulon of the EMD as they discuss on innovative ways of to include patient involvement in medicines development. The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developi...
Jun 20, 2017•54 min
Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He's joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals, and Dr Chandra Ramanathan at Bayer Healthcare. Save the date for the 4th annual IO360° conference, t...
Jun 20, 2017•44 min
Originally recorded during the 3rd annual Immuno-Oncology 360° in February 2017, this panel discussion addresses clinical challenges within immuno-oncology. One of the IO360° lead advisors, Dr James Gulley of the National Cancer Institute, moderates the session between Merck’s Dr Roy Baynes, nanoString Technologies’ Dr Alessandra Cesano, MD Anderson’s Dr Patrick Hwu, and inVentiv Health’s Robert Millham. Dr Hwu and Dr Baynes are also speaking on the 2nd annual Rational Combinations 360° program ...
Jun 20, 2017•46 min
During the preclinical science plenary session from 2017's Immuno-Oncology 360° conference, Dr Charles Drake's talks about "Sequencing of Combination Agents." Dr Drake is Director, Genitourinary Oncology and Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. Previously, he was an associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine. He also serves as Co-Director of the Prostate...
Jun 16, 2017•19 min
At 2016's Rational Combinations 360° meeting, Dr Patrick Hwu of MD Anderson Cancer Center delivered a keynote address on the future outlook behind combination immunotherapy. Dr Hwu addresses innovations behind combination therapy, specifically focusing on what’s next after checkpoint combinations and whether combination of adoptive T-cell therapy and anti-checkpoint inhibitor therapies are the next wave. Dr Hwu serves as a lead advisor for the 2nd annual Rational Combinations 360° meeting, which...
Jun 07, 2017•32 min
We are delighted to bring the Patients as Partners US event to Europe on February 6-7 in London. We would like to thank our European attendees at the US conference for challenging and encouraging us to bring the conference to Europe. The goal of creating patient centricity as the ecosystem within pharma can not be achieved without patient involvement. Patients as Partners Europe is accredited by Patients Included and addresses what matters most to patients to enable them to engage in clinical re...
Jan 26, 2017•6 min
The 3rd annual DPharm Europe: Disruptive Innovations to Advance Clinical Trials event is led by Co-Chairs Dr Sue Collier (GSK) and Dr Jeff Kasher (Patients Can’t Wait). This radio blogcast gives a five minute overview of the event, which presents global case studies on: Real World Clinical Trial Strategies and ResultsNew Leadership in Driving Clinical Trial InnovationStrategies to Validate the Siteless TrialCommunity Outreach and Education in Clinical TrialsNew Financial ModelsPatient Involvemen...
Jan 26, 2017•6 min
The 3rd annual Immuno-Oncology 360° event takes place February 1-3, 2017 in NYC. Lead advisors, Dr Axel Hoos (GSK) and Dr James Gulley (NCI) co-present a program that provides a 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. In this brief radio blog post, get a five minute overview on what to expect at...
Jan 26, 2017•5 min
Members of the DPharm team engage in an informal conversation to highlight what's happening in innovation and the latest thinking to disrupt clinical trials at the 6th annual event. Also discussed is a brief history of how this conference dedicated to applying disruptive thinking to clinical trials came to be. This conversation is well worth listening to if you plan to attend DPharm or want to get a sense of the quality and depth this program brings to clinical trial executives. DPharm takes pla...
Aug 12, 2016•34 min
Pfizer’s “Blue Sky” approach to transforming clinical research in Parkinson’s disease is an inspiring example of patient-centric innovation. Conference Forum's, Valerie Bowling welcomes co-host, Ed Miseta, Clinical Leader.com in a discussion with members of Pfizer’s "Blue Sky" team. Together they discuss the vision, goals and journey in taking a new approach to advancing drug development. More specifically, the Blue Sky team talks about their partnership with IBM, (first of its kind) decisions o...
Aug 10, 2016•32 min
This discussion provides helpful approaches for Chief Medical Officers (CMOs) and other R&D leadership in biotech on how to communicate effectively in times of good, bad or unexpected news. Also discussed in this program are factors to evaluate for the discontinuation of a program. Dr Mark Weinberg, Chief Medical Officer and Managing Director of Halloran Consulting Group will be joined by Dr Lee Allen, CMO, Argos Therapeutics to discuss strategic communication strategies CMOs/R&D leaders...
May 16, 2016•42 min
What is the quality, capacity and efficiency of running clinical trials in Puerto Rico? In this discussion we speak with Dr Myrto Lee, Director, PwC'sStrategy&, UK and Dr Kosmas Kretsos, Executive Director of the Puerto Rico Consortium for Clinical Investigation to learn about key initiatives and outcomes so far to make running clinical trials more attractive in Puerto Rico. For more information about conductingclinical trials in Puerto Rico, please visit www.PRCCI.org. Why consider Puerto R...
May 13, 2016•42 min
Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised by a wealthy individual primarily, in return for being in the trial. At DPharm Europe, Pfizer's Craig Lipset interviewed on stage Alexander to share his story. We are delighted to present the journey and latest updates...
Apr 07, 2016•36 min
Generic drugs can be repurposed to create effective treatments in unsolved diseases. However, there is no economic incentive for industry to pay for a clinical validation and regulatory approval process for most generic drug repurposing because it will not achieve the necessary ROI. Cures Within Reach, FindaCure, Numbers For Good and the National Health Service in England are working together to the create a new economic solution to this problem by piloting the first ever Rare Disease Generic Dr...
Apr 01, 2016•50 min
Pharmatalk's Valerie Bowling welcomes Anton (Tony) Hoos, MD, PhD, Head of Medical, Amgen Europe and Marc Boutin, JD, Chief Executive Officer, National Health Council. We address how industry and patients can work together to incorporate the patient voice in drug development and to improve patient's experience in clinical trials. We examine the current challenges and barriers to patient involvement, progress and next steps. Host: Valerie Bowling, Executive Producer, PharmaTalk Radio Guests: Anton...
Jan 21, 2016•40 min
PharmaTalk Radio's Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD,National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what's currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they also address: Ipilumumab/Nivo/Pembro challengesWhat can we learn from the development of sipuleucel-T that ...
Dec 21, 2015•58 min
